Promising cocktail aims to save voice boxes in head and neck cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of written informed consent, with full understanding of and agreement to comply with study requirements and the visit schedule. 2. Age 18-75 years (inclusive) at the time of informed consent; either sex. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 4. Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of the head and neck as assessed by the investigator. 5. Documented EGFR-positive tumor. 6. No prior systemic therapy for head and neck squamous cell carcinoma. 7. At least one measurable lesion per RECIST v1.1. 8. Estimated life expectancy ≥ 12 weeks. 9. Adequate bone-marrow and organ function. Exclusion Criteria: 1. Known hypersensitivity to any component of PD(L)-1 inhibitors, paclitaxel, or cisplatin. 2. Prior or concurrent malignancy (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma disease-free for \>5 years). 3. Uncontrolled cardiac symptoms or clinically significant cardiac disease. 4. Previous therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or receipt of therapeutic cancer vaccines or live vaccines within 4 weeks before first study-dose administration. 5. Failure to recover to ≤ Grade 1 (per CTCAE) from prior anti-tumour therapy-except alopecia or residual neurotoxicity related to prior platinum-before first study dose. 6. Severe infection (\> CTCAE Grade 2) within 4 weeks before first study dose. 7. Active autoimmune disease or documented autoimmune-disease history requiring systemic therapy. 8. History of immunodeficiency, including positive HIV test, congenital or acquired immunodeficiency syndromes, or prior solid-organ or allogeneic bone-marrow transplantation. 9. History of interstitial lung disease or non-infectious pneumonitis. 10. Evidence of active tuberculosis infection on history or CT imaging. 11. Active hepatitis B (HBV DNA ≥ 500 IU/mL or ≥ 2,500 copies/mL). 12. History of substance abuse, alcohol abuse, or drug addiction. 13. Pregnant or lactating women. 14. Any condition that, in the investigator's opinion, could necessitate premature withdrawal from the study.